Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19174701 | 0.88 | P2RY2 (0.59) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL18855474 | 0.88 | P2RY2 (0.59) | DUTP2RY2P2RY4P2RY6 | |
| SCHEMBL18840555 | 0.87 | TK1 (0.54) | — | |
| SCHEMBL18844352 | 0.84 | POLB (0.49) | P2RY2P2RY4P2RY6 | |
| SCHEMBL18840575 | 0.83 | P2RY2 (0.40) | P2RY2P2RY4P2RY6 | |
| SCHEMBL18844358 | 0.80 | PRMT5 (0.39) | — | |
| SCHEMBL23734157 | 0.79 | P2RY2 (0.56) | DUTP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL24905837 | 0.79 | P2RY2 (0.56) | DUTP2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL18840558 | 0.76 | POLB (0.51) | P2RY2 | |
| SCHEMBL24023167 | 0.74 | POLB (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137869-A1 | METHODS FOR SYNTHESIZING NUCLEOTIDE ANALOGUES WITH DISULFIDE LINKERS | IsoPlexis Corporation | 2017-05-18 | — | — | US | disclosed |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137869-A1 | METHODS FOR SYNTHESIZING NUCLEOTIDE ANALOGUES WITH DISULFIDE LINKERS | RNGTT, NT5C3B, DUT | DUT 3/4885P2RY2 1196/4885P2RY4 827/4885 |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | DUT 3/4885P2RY2 413/4885P2RY4 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.